Wenyue Hu

PF-06463922, an ALK/ROS1 Inhibitor, Overcomes Resistance to First and Second Generation ALK Inhibitors in Preclinical Models

Helen Y. Zou, Luc Friboulet, David P. Kodack et al. · Cancer Cell · 2015 · 463 citations · Full text

Medicine, Oncology, Pharmacology +14

Spectrum and Degree of CDK Drug Interactions Predicts Clinical Performance

Ping Chen, Nathan V. Lee, Wenyue Hu et al. · Molecular Cancer Therapeutics · 2016 · 422 citations

Medicine, Oncology, Pharmacology +9

PF-06463922 is a potent and selective next-generation ROS1/ALK inhibitor capable of blocking crizotinib-resistant ROS1 mutations

Helen Y. Zou, Qiuhua Li, Lars D. Engstrom et al. · Proceedings of the National Academy of Sciences · 2015 · 269 citations · Full text

Medicine, Oncology, Pharmacology +15

Robust estimation of bacterial cell count from optical density

Jacob Beal, Natalie G. Farny, Traci Haddock-Angelli et al. · Communications Biology · 2020 · 231 citations · Full text

Life Sciences, Microbiology, Bacteriology +12

Mechanistic Investigation of Bone Marrow Suppression Associated with Palbociclib and its Differentiation from Cytotoxic Chemotherapies

Wenyue Hu, Tae Sung, Bart Jessen et al. · Clinical Cancer Research · 2015 · 167 citations

Medicine, Oncology, Pharmacology +15